These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2151109)

  • 1. [Endometrioid carcinoma of the prostate: a histogenetic dilemma with therapeutic implications].
    Angulo Cuesta J; López JI; Unda Urzaiz M; Eizaguirre Zarza B; Flores Corral N
    Arch Esp Urol; 1990; 43(9):979-81. PubMed ID: 2151109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
    Tauveron I; Hermabessière J
    Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
    Robinson MR
    Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of virginal prostatic cancer with cyproterone acetate].
    Maier U
    Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
    Oosterlinck W; Mast P
    Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endometrioid adenocarcinoma of the prostate: report of 3 cases].
    Uemura M; Nakagawa M; Kanno N; Nishimura K; Miyoshi S; Kawano K
    Hinyokika Kiyo; 2004 Nov; 50(11):825-8. PubMed ID: 15628548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced prostatic cancer.
    Sogani PC; Fair WR
    Urol Clin North Am; 1987 May; 14(2):353-71. PubMed ID: 2953100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyproterone acetate in the management of prostatic cancer.
    Tunn UW
    Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chronic myeloid leukemia and carcinoma of the prostate].
    Papineschi F; Bonini R; Pistolisi D; Spremolla G
    Sangre (Barc); 1989 Oct; 34(5):383. PubMed ID: 2533407
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognosis of prostate carcinoma. Actual standing (author's transl)].
    Heising J; Allhoff E
    Z Hautkr; 1981 Jun; 56(11):705-14. PubMed ID: 6167082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cyproterone acetate in the treatment of post-orchiectomy flushing].
    Jansen JE; Hendriksen ON
    Ugeskr Laeger; 1989 Feb; 151(9):560-1. PubMed ID: 2522257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
    Tobelem G; Arvis G
    Therapie; 1988 May; 43(3):179-82. PubMed ID: 2971278
    [No Abstract]   [Full Text] [Related]  

  • 16. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
    Isaacs JT
    Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exophthalmos caused by orbital metastasis of prostatic carcinoma].
    Romero Pérez P; Pelluch Auladell A; Lobato Encinas JJ; Megías Garrigos J; García Vicente C; Pérez-Llorca LA; Mira Llinares A
    Arch Esp Urol; 1991 Mar; 44(2):191-4. PubMed ID: 1714262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiandrogen treatment with cyproterone acetate in with virilizing symptoms].
    Abrahamsson L; Hackl H; Lindström B; Martinik J
    Lakartidningen; 1981 Nov; 78(47):4259-61. PubMed ID: 6460145
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Aug; 80(4):764-75. PubMed ID: 9264361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.